enVVeno Medical Corporation provided an update on enrollment for its ongoing SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) U.S. pivotal study for the VenoValve and announced two upcoming investor events. The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.285 USD | +2.03% | +6.52% | +1.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.75% | 68.98M | |
+1.68% | 42.75B | |
+47.70% | 41.61B | |
+12.42% | 41.34B | |
-8.83% | 26.59B | |
+6.45% | 25.49B | |
-23.01% | 18.12B | |
+30.33% | 12.24B | |
-2.34% | 11.76B | |
+8.43% | 11B |
- Stock Market
- Equities
- NVNO Stock
- News enVVeno Medical Corporation
- Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study